Background-Toll-like receptors (TLRs) have long been considered to be major culprits in the development of atherosclerosis, contributing both to its progression and clinical complications. However, evidence for most TLRs beyond TLR2 and TLR4 is lacking. Methods and Results-We used experimental mouse models, human atheroma cultures, and well-established human biobanks to investigate the role of TLR7 in atherosclerosis. We report the unexpected finding that TLR7, a receptor recognizing self-nucleic acid complexes, is protective in atherosclerosis. In Apoe Ϫ/Ϫ mice, functional inactivation of TLR7 resulted in accelerated lesion development, increased stenosis, and enhanced plaque vulnerability as revealed by Doppler ultrasound and/or histopathology. Mechanistically, TLR7 interfered with macrophage proinflammatory responses to TLR2 and TLR4 ligands, reduced monocyte chemoattractant protein-1 production, and prevented expansion of Ly6C hi inflammatory monocytes and accumulation of inflammatory M1 macrophages into developing atherosclerotic lesions. In human carotid endarterectomy specimens TLR7 levels were consistently associated with an M2 anti-inflammatory macrophage signature (interleukin [IL]-10, IL-1RA, CD163, scavenger and C-type lectin receptors) and collagen genes, whereas they were inversely related or unrelated to proinflammatory mediators (IL-12/IL-23, interferon beta, interferon gamma, CD40L) and platelet markers. Moreover, in human atheroma cultures, TLR7 activation selectively suppressed the production of key proatherogenic factors such as monocyte chemoattractant protein-1 and tumor necrosis factor without affecting IL-10. Conclusions-These findings provide evidence for a beneficial role of TLR7 in atherosclerosis by constraining inflammatory macrophage activation and cytokine production. This challenges the prevailing concept that all TLRs are pathogenic and supports the exploitation of the TLR7 pathway for therapy. (Circulation. 2012;126:952-962.)
C hronic inflammation is an integral part of the pathogenesis of atherosclerosis. 1, 2 Accumulation of lipoproteins in the vessel wall, especially at areas of disturbed blood flow such as bifurcations and the lesser curvature of the aortic arch, induces a chronic inflammatory response characterized by the mobilization of monocytes in the periphery, the infiltration of macrophages, dendritic cells, and lymphocytes in the arterial intima, and the expression of proinflammatory cytokines, chemokines, and matrix metalloproteinases. This leads to luminal narrowing and often plaque rupture and myocardial infarction or stroke, the most severe clinical complications of atherosclerosis. Therefore, identifying ratelimiting molecular processes and pathways that contribute to the development or persistence of inflammation in the vessel wall is key to the future treatment of this disease. 3 
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Toll-like receptors (TLRs) have recently taken center stage in atherosclerosis research by virtue of their ability to drive sterile inflammation in the vessel wall. Under the current paradigm, TLRs promote atherogenesis through the disruption of endothelial cell integrity, the induction and sustained expression of inflammatory cytokines and chemokines, and the infiltration and activation of inflammatory monocytes/ macrophages in developing plaques. In agreement with this model, TLRs (1, 2, 4, and 6) are increased in human atherosclerotic lesions, 4 -6 in cells of the monocyte/macrophage lineage and resident vascular cells, whereasTLR2 and TLR4 polymorphisms have been associated with the extent of atherosclerosis in some studies, although not others. 7 Several endogenous TLR ligands relevant to atherosclerosis have also been described, including modified lipoproteins, oxidized lipids, and self-ligands released in response to hypercholesterolemia, tissue stress, or necrosis. [7] [8] [9] Moreover, TLR2 signaling through myeloid differentiation factor 88 (MyD88) and nuclear factor kappa B has been shown to account for increased inflammation and matrix degradation in an ex vivo culture system of human atherosclerotic plaques, 10, 11 whereas functional TLR2, TLR4, and MyD88 have been demonstrated to be critically required for the development of atherosclerosis in experimental mouse models fed a high-fat diet. 6, [12] [13] [14] [15] [16] [17] More recently, TLR6 has also been linked to the development of atherosclerosis by forming heterodimeric complexes with TLR4 involved in the recognition of oxidized lipoproteins. 18 In contrast, genetic deletion of TLR3 has suggested a protective role of this receptor in arterial injury and early atherogenesis, whereas systemic administration of TLR3 agonists has yielded contradictory results, 19, 20 highlighting the need for more detailed investigation into the role of other TLRs in atherosclerosis.
TLR7 is an endosomal TLR that recognizes viral singlestranded RNA and self-RNA released from necrotic cells often complexed with cationic antimicrobial peptides such as LL37 and ␣-defensins or antibodies. 21, 22 It is expressed in subsets of monocytes, macrophages, dendritic cells, B cells, and eosinophils and is upregulated in intermediate and advanced atherosclerotic lesions of femoral arteries of patients with peripheral artery disease. 23 The main known function of TLR7 is in antiviral immunity, although additional proinflammatory, anti-inflammatory, and immunoregulatory activities of TLR7 during chronic inflammation have also been described. 24, 25 Still, the functional role of TLR7 in atherosclerosis remains unknown. Here, we present the surprising finding that TLR7 is protective in atherosclerosis by shaping monocyte/macrophage function toward an alternatively activated antiatherogenic phenotype. This challenges the current paradigm that all TLRs are pathogenic in atherosclerosis and has broader implications for the role of innate immunity in this disease.
Methods

Experimental Animals
Apolipoprotein E-deficient (Apoe Ϫ/Ϫ ) mice on a C57BL/6J background were crossed with TLR7-deficient (Tlr7 Ϫ/Ϫ ) mice originally obtained from Shizuo Akira (Osaka University) and backcrossed to the C57BL/6J background for Ͼ10 generations. Mice were fed a normal chow diet containing 18.5% protein and 5.5% fat (Harlan Tekland) and analyzed at various time points as indicated. For the assessment of macrophage responsiveness to TLR2 stimulation in vivo, Apoe Ϫ/Ϫ and Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice were injected intraperitoneally with 20 g endotoxin-free lipoteichoic acid (Invivogen) in 200 L sterile PBS, euthanized after 3 hours, and serum collected. More details are available in the online-only Data Supplement.
Doppler Ultrasonography
Echocardiographic studies were performed in anesthetized mice using a Vivid 7, GE ultrasound system with a 13 MHz linear transducer and a 6 MHz-pulsed Doppler probe as detailed in the online-only Data Supplement.
Analysis of Atherosclerotic Lesions
Oil Red O (Sigma-Aldrich) and Picro-Sirius Red (Sigma-Aldrich) stained serial sections of the aortic valve, spanning a 500-m area, and Sudan IV (Sigma-Aldrich) stained entire aortas were analyzed using the ImageJ software (Wayne Rasband).
Immunofluorescence-Immunohistochemistry
Mouse aortic sinus cryosections were stained with anti-mouse CD68 (clone FA-11; Serotec), alpha smooth muscle actin (clone 1A4, Sigma-Aldrich), inducible nitric oxide synthase (iNOS; ab15323, Abcam), or isotype control monoclonal antibodies and counterstained with 4Ј,6-diamidino-2-phenylindole (Molecular Probes). Positive staining areas or colocalization were quantified by use of the ImageJ software (Wayne Rasband). Detailed protocols are available in the online-only Data Supplement.
Quantification of Plaque Necrosis
Plaque necrosis was determined by drawing boundary lines around regions free of 4Ј,6-diamidino-2-phenylindole staining and quantifying the region area by using the ImageJ analysis software (Wayne Rasband). A 3000-m 2 threshold was implemented to avoid counting regions that may not represent substantial areas of necrosis. 17 
Flow Cytometry
Blood and spleen were processed and stained with fluorochromeconjugated monoclonal antibody combinations for CD115, CD11b, Ly6C, CD45, and appropriate IgG isotype controls (eBioscience). Flow cytometry was performed on a Beckman-Coulter FC-500 analyzer, and data were analyzed by using Kaluza software (Beckman Coulter).
Serum Measurements
Serum concentrations of total cholesterol and triglycerides were determined by use of kits from Cayman Chemicals. Serum cytokines were measured by ELISA by using commercially available kits (eBioscience).
Isolation of mRNA and Quantitative Real-Time Polymerase Chain Reaction
Real-time quantitative polymerase chain reaction was performed with SYBR GreenER qPCR SuperMix Universal (Invitrogen). Target mRNA levels were expressed relative to GAPDH. Primer sets are shown in the online-only Data Supplement.
Peritoneal Macrophage Activation
Peritoneal macrophages from Apoe Ϫ/Ϫ and Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice were cultured with various doses of lipoteichoic acid and supernatants measured after 20 hours by ELISA using commercially available kits (eBioscience).
Salagianni et al Toll-Like Receptor 7 Protects From AtherosclerosisVascular Specimens and Genome-Wide Expression Array Studies
Genome-wide expression array studies were conducted in human carotid plaque samples from the Biobank of Karolinska Endarterectomies (BiKE) study. 26 In brief, carotid lesions (nϭ127) and control tissue obtained from normal arteries of organ donors (nϭ10) were analyzed by using Affymetrix HG-U133A Genechip arrays (http:// www.affymetrix.com). More detailed information is provided in the online-only Data Supplement.
Human Atheroma Cell Cultures
Single-cell suspensions from carotid endarterectomies from patients undergoing revascularization procedures for symptomatic carotid disease at Charing Cross Hospital, London, were obtained as previously described. 10, 11 Cells were cultured in the presence or absence of 1 g/mL imiquimod (Invivogen, CA) and cytokine levels quantified by Luminex 100 by using Fluorokine Multianalyte kits from R&D Systems.
Statistical Analysis
Statistical significance of differences was assessed using the parametric Student t test for normally distributed data and the nonparametric Mann-Whitney U (MWW) test for skewed data that deviate from normality. For associations between TLR7 levels and macrophage markers, the Pearson correlation coefficient was used. Differences were considered significant when PϽ0.05.
Results
Functional Inactivation of TLR7 Exacerbates Atherosclerosis in Apoe ؊/؊ Mice
To examine whether TLR7 is involved in the pathogenesis of atherosclerosis, we generated Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ and compared them with Apoe Ϫ/Ϫ mice (online-only Data Supplement Figure I ). Both Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ and Apoe Ϫ/Ϫ mice appeared healthy, reproduced according to Mendelian ratios and exhibited no obvious abnormalities (data not shown). There was no significant difference on weight gain or triglyceride levels between the 2 groups, whereas cholesterol levels were reduced in Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice (online-only Data Supplement Table I ). However, Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice developed substantially larger atherosclerotic lesions as they aged. Quantification of Oil Red O staining at the level of the aortic sinus revealed a significant increase in lesion size in 18-and 26-week but not 10-week old Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice in comparison with Apoe Ϫ/Ϫ controls ( Figure 1A and 1B). This was accompanied by similarly increased accumulation of CD68 ϩ macrophages ( Figure 1C ). En face staining with Sudan IV of the aorta also revealed a substantial increase of the total lesion area in Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice in comparison with Apoe Ϫ/Ϫ controls ( Figure 1D ). Finally, Doppler ultrasound analysis showed increased mean and peak carotid velocity indices in Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice in comparison with Apoe Ϫ/Ϫ mice (Table) , in agreement with enhanced atherosclerosis. In contrast, there was no statistically significant difference in overall left ventricular function between the 2 groups, although an increase in left ventricular end diastolic diameter was apparent in Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice (Table) . Posterior wall thickness in diastole did not differ between the 2 groups either, suggesting that chronic left ventricular outflow obstruction was not present. Consistently, the r/h ratio, which is an indicator of left ventricular wall stress, was not changed. All transvalvular aortic blood flow indices were also similar between the 2 groups. Taken together, these observations demonstrate that functional TLR7 is essential for limiting experimental atherosclerosis in mice.
Functional Inactivation of TLR7 Enhances Features of Plaque Vulnerability in Apoe ؊/؊ Mice
Although lesion size accurately reflects atherosclerosis progression, plaque morphology is a more important predictor of plaque disruption and acute clinical events in humans. 27, 28 To investigate whether TLR7 also affects the plaque phenotype, we evaluated several key parameters as surrogate markers for lesion vulnerability. We found that plaques from 26-week-old Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice exhibited increased lipid content (Figure 2A) and were enriched in CD68 ϩ macrophages in comparison with Apoe Ϫ/Ϫ mice ( Figure 2B ). In agreement with that, the presence of alpha smooth muscle actin positive cells was reduced in Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice ( Figure 2C ) as was the accumulation of collagen and the thickness of the fibrous cap ( Figure 2D ). It is noteworthy that Tlr7
Apoe
Ϫ/Ϫ mice also exhibited increased necrotic core size defined as acellular 4Ј,6-diamidino-2-phenylindole Ϫ areas containing remnants of cells and extracellular lipid ( Figure 3 ). Because enhanced plaque necrosis, lipid deposition, and macrophage infiltration, reduced smooth muscle cell and collagen presence, and fibrous cap formation are features attributed to a more vulnerable plaque phenotype, 27,28 these findings suggest that deficient TLR7 function also promotes lesion instability in Apoe Ϫ/Ϫ mice.
Tlr7
؊/؊
Apoe
؊/؊ Mice Exhibit Increased Levels of Inflammatory Ly6C hi Monocytes in the Circulation and Inflammatory M1 Macrophages in Developing Atherosclerotic Lesions
To get insight into the mechanism by which TLR7 modulates atherosclerosis, we analyzed parameters related to monocyte/ macrophage mobilization and proatherogenic function. We found that Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice exhibited higher serum levels of monocyte chemoattractant protein-1 (MCP-1), a key proatherogenic cytokine orchestrating both monocyte expansion in the periphery and accumulation of macrophages in developing atherosclerotic lesions ( Figure 4A ). 29, 30 In contrast, other inflammatory cytokines such as interleukin (IL)-12/23p40, IL-6, IL-10, and tumor necrosis factor (TNF) were not detectable in the serum (data not shown). We then examined whether TLR7 regulates the balance between inflammatory Ly6C hi and patrolling Ly6C lo monocyte subsets, the counterparts of human CD14 ϩ CD16 Ϫ and CD14 ϩ CD16 ϩ cells. 31 Ly6C hi monocytes selectively express CCR2 and respond to MCP-1 during hypercholesterolemia to expand in the periphery and migrate into the vascular wall. [32] [33] [34] In agreement with the increased MCP-1 levels, we found that Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice exhibited higher levels of Ly6C hi monocytes relative to total (CD11b ϩ CD115 ϩ ) mono- 
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cytes both in the blood ( Figure 4B ) and spleen ( Figure 4C ) in comparison with Apoe Ϫ/Ϫ mice, whereas the frequency of Ly6C lo monocytes was reduced. The less abundant Ly6C int monocytic population was also reduced. This was associated with increased accumulation of inflammatory M1 macrophages in the aorta of Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice as revealed by the higher levels of proinflammatory cytokines and M1 macrophage markers such as IL-12/23p40, TNF, MCP-1, and iNOS ( Figure 4D and 4E) . 35, 36 In contrast, there were no differences observed in the expression of the antiinflammatory cytokine IL-10 or the M2 markers Arg1 or Ym1 between the 2 groups ( Figure 4D ), whereas differences in tissue remodeling factors and enzymes were also seen (online-only Data Supplement Figure II) . IL-23p19 and IL-17A were not detectable (data not shown). These data indicate that TLR7 acts as a brake to limit inflammatory monocyte/macrophage differentiation and activation in atherosclerosis.
TLR7 Is Essential for Constraining Inflammatory Monocyte/Macrophage Activation and Cytokine Production
We next investigated how TLR7 affects macrophage function and proinflammatory cytokine production in the context of atherosclerosis. Surprisingly, we found that macrophages from Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice exhibited increased responsiveness to TLR2 or TLR4 stimulation in comparison to Apoe Figure 5B ). This was not due to differences in the expression of TLR2 or TLR4 nor critical downstream signaling components such as MyD88, Mal/TIRAP, TRIF, TRAM, IRAK1, IRAK2, Tollip, TRAF6, IKK2, or nuclear factor kappa B genes between the 2 groups (online-only Data Supplement Figure IV) , although the induction of a compensatory TLR response in the absence of functional TLR7 is still a possibility. Because TLR2 and TLR4 are critically involved in macrophage activation during the development/ progression of atherosclerosis, [12] [13] [14] [15] [16] [17] and MCP-1 is a ratelimiting chemokine for atherogenesis, 29,37 these findings suggest that TLR7 limits the development of atherosclerosis by interfering with monocyte/macrophage activation and MCP-1 production.
TLR7 Is Associated With M2 Macrophage Markers and a Less Inflammatory Plaque Phenotype in Human Atherosclerotic Lesions
Finally, we investigated the role of TLR7 in human atherosclerosis. Large-scale transcriptional profiling analysis of human atheromata from the Biobank of the Karolinska Endarterectomies study (BiKE) 26 and the Tampere Vascular Study (TVS) 38 revealed that TLR7 was consistently upregulated at the mRNA level in atherosclerotic carotid and femoral arteries, and abdominal aortas in comparison with normal iliac arteries in BiKE or internal thoracic arteries in TVS ( Figure 6A and online-only Data Supplement Table II) . In BiKE, where several clinical variables were available for each patient, TLR7 expression was found to be reduced on active cigarette smoking ( Figure 6B ) but was unaffected by diabetes, hypertension, obesity, sex, history of symptoms, or medication (online-only Data Supplement Table III) . TLR7 mRNA levels strongly correlated with the pan-leukocyte marker CD45 and the monocyte/macrophage marker CD14, exhibited a weak correlation with the T-cell marker CD3, and the mast cell marker TPSAB1, and lacked correlation with the B-cell marker CD19 and the smooth muscle cell marker alpha smooth muscle actin, suggesting that TLR7 expression in plaques is mostly derived from CD14 ϩ monocytes/macrophages (online-only Data Supplement Figure V) .
We next examined whether TLR7 expression was functionally important. We found that addition of the specific TLR7 agonist imiquimod to mixed cell cultures from carotid endarterectomy specimens 10, 11 inhibited the expression of MCP-1 and TNF, which are associated with a more inflammatory macrophage phenotype, whereas the expression of IL-10 was spared ( Figure 6C ). IL-12 and IL-23 were below the detection limits. Consistently, in human atheromata from BiKE, TLR7 mRNA levels were positively associated with the expression of M2 macrophage markers such as the anti-inflammatory cytokine IL-10, IL-1 receptor antagonist (IL-1RN), CD163, scavenger receptors, and C-type lectin receptors ( Figure 6D ), whereas they were inversely related to proinflammatory cytokines and M1 macrophage markers such as IL-23p19, iNOS, and interferon beta, and lacked any association with IL-12p35, IL-12/23p40, and interferon gamma ( Figure 6D ). Additionally, TLR7 mRNA levels were positively associated to collagen genes (Col1A1, Col3A1, Col4A1), fibronectin-1, fibrillin-1, and tissue plasminogen activator (PLAT) expression, and negatively related to platelet markers and CD40 ligand ( Figure 6E ). Despite these 
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findings, TLR7 mRNA expression was not associated with a more stable/fibrotic histopathologic plaque phenotype in either the TVS or the University of Athens carotid endarterectomies cohort (online-only Data Supplement Figure VI) . Taken together, these findings suggest a link between higher TLR7 expression and reduced inflammation, decreased presence of platelets, and increased deposition of collagen and extracellular matrix, all predictive markers of a more stable plaque phenotype, 27, 28, 39 and highlight the need for further studies into the role of TLR7 in plaque vulnerability.
Discussion
Although TLRs have been incriminated for the development of atherosclerosis, evidence for most TLRs beyond TLR2 and TLR4 is lacking. We now reveal that TLR7 is upregulated in human atheromata and exhibits a novel, previously unsuspected beneficial role in atherosclerosis. In Apoe Ϫ/Ϫ mice, an established animal model of atherosclerosis, functional inactivation of TLR7 worsens disease and promotes a more vulnerable plaque phenotype. Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice exhibit accelerated lesion development and increased stenosis, whereas plaques from Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice enhanced necrotic core formation, lipid deposition, macrophage accumulation, and proinflammatory cytokine production, and reduced smooth muscle cell and collagen presence. Moreover, in human carotid endarterectomy specimens, TLR7 mRNA levels are positively associated with anti-inflammatory cytokines and M2 macrophage markers (such as IL-10, IL-1RA, CD163, scavenger and C-type lectin receptors), and collagen genes, although they are inversely related/unrelated to proinflammatory mediators (such as IL-12/IL-23, interferon beta, interferon gamma, CD40L) and platelet markers. Lower TLR7 mRNA levels are also associated with active cigarette smoking but not other traditional risk factors, the histopathologic plaque phenotype, or disease symptomatology, possibly because of the sample size used or variable time interval between symptoms and endarterectomy. Altogether, our findings demonstrate that TLR7 is protective in atherosclerosis and challenge the prevailing paradigm that all TLRs are pathogenic.
Central to the protective role of TLR7 in atherosclerosis is its ability to shape monocyte/macrophage function toward an anti-inflammatory phenotype. Mechanistically, this involves inhibition of (1) inflammatory Ly6C hi monocyte expansion in the periphery and (2) inflammatory M1 macrophage accumulation and activation in developing atherosclerotic lesions through a process orchestrated by MCP-1. Accordingly, 
Tlr7
Ϫ/Ϫ Apoe Ϫ/Ϫ mice and Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ macrophages exhibit increased production of MCP-1, whereas TLR7-stimulated human carotid atheroma cultures reduced levels. How exactly MCP-1 is triggered in vivo is not entirely clear, but it is tempting to speculate that TLR2 and TLR4 are involved in this response. TLR2 and TLR4 are major pathogenic factors involved in driving atherogenesis through the recognition of oxidized lipids and lipoproteins, and fatty acids, induced in response to hypercholesterolemia. 7, 8 Deficiency of TLR2, and to a lower extent TLR4, reduces the production of MCP-1 and the development of atherosclerosis in experimental mouse models, whereas activation of TLR2 or TLR4 with bacterial ligands or the apolipoprotein CIII fraction of triglyceride-rich lipoproteins induces MCP-1 expression and exacerbates disease. 12, 15, 16, 40 Similarly, neutralization of TLR2 or its downstream adaptor molecule MyD88 suppresses the production of MCP-1 in human atheroma cultures. 10 In addition, activation of TLR2 and TLR4 with low amounts of bacterial ligands effectively mobilizes Ly6C hi monocyte emigration from the bone marrow and recruitment to inflammatory sites through an MCP-1-dependent mechanism. 41 Thus, TLR2 and TLR4 constitute the most likely triggers of MCP-1 production in vivo.
TLR7-mediated protection also involves modulation of macrophage polarization. Inflammatory M1 macrophages and M1-associated cytokines contribute to the development and vulnerability of plaques, whereas M2 macrophages are considered to be beneficial through the paracrine antiinflammatory effects they exert on M1 macrophages and the improved clearance of apoptotic cell debris. 42, 43 Accordingly, the M1/M2 ratio is proportional to the progression of lesion size in Apoe Ϫ/Ϫ mice, 35 whereas factors that promote a proinflammatory M1 macrophage phenotype such as TLR2 and TLR4 ligands or G2A deficiency result in an increased disease burden in the same mice. 12, 15, 36, 44 Thus, the increased expression of inflammatory cytokines and M1 macrophage markers in Tlr7 Ϫ/Ϫ Apoe Ϫ/Ϫ mice and the positive association of TLR7 levels with M2 macrophage markers in human carotid plaques reveal an additional mechanism of atheroprotection promoted by TLR7. Although this may be directly related to the levels of inflammatory Ly6C hi monocytes (as observed in Apoe Ϫ/Ϫ mice), which produce high levels of M1-type inflammatory cytokines and are therefore likely precursors of inflammatory M1 macrophages, further studies will be needed to confirm this possibility. A role of TLR7 in M2 macrophage polarization may at first seem intriguing. However, it is not without precedent. Repetitive triggering of TLR7 in mice has been shown to suppress the production of proinflammatory M1 cytokines such as IL-12/23p40, IL-6, and TNF without affecting, or in some cases even increasing, the production of IL-10. 45, 46 TLR7 stimulation has also been shown to induce cross-tolerance to subsequent TLR2 and TLR4 stimulation that lasts for days, 46 In addition, combination of a TLR ligand and immune complexes, prostaglandins, apoptotic cells, IL-10, or adenosine, all signals relevant to atherosclerosis, has been shown to induce the generation of "regulatory" M2-like macrophages characterized by high expression of CD163 and IL-10, low levels of TNF and IL-1␤, and absence of IL-12 and IL-23. 47 It is therefore possible that, in the context of atherosclerosis, TLR7 favors the generation of M2 macrophages as part of a protective immune response aiming at restoring homeostasis in the vessel wall.
Our findings broaden our understanding of the role of innate immune receptors in the development of atherosclerosis. It has been well established over the past few years that TLR2 and TLR4 respond to danger signals induced during hypercholesterolemia or tissue stress to promote macrophage accumulation and inflammation in the vessel wall. TLR6 is also part of this process by acting as the binding partner of TLR2 in the detection of oxidized lipoproteins. This response is further enhanced through the recognition of cholesterol crystals by the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome. 48 We now expand this scheme by adding TLR7, a receptor that senses viral and self-single-stranded RNA. We show that TLR7 inhibits atherosclerosis and promotes plaque stabilization by interfering with macrophage activation and accumulation into developing atherosclerotic lesions. This is complemented by our recent finding that TLR3 may also exert beneficial effects in atherosclerosis, 19 and raises the possibility that this protective function of TLR7 may represent a shared feature of nucleic acid-sensing TLRs. Although the exact ligands triggering TLR7 activation in the context of atherosclerosis are not known, self-RNA released during cell death or necrosis in advanced atherosclerotic lesions is a strong candidate (onlineonly Data Supplement Figure VII) . These findings have wider implications for the way the immune system is fine tuned in response to danger, because they uncover a new pathway that promotes homeostatic or repair responses in the atherosclerotic wall.
Our study is not without potential limitations. First, the size of the cohorts used to investigate correlations between plaque TLR7 expression and disease parameters (including plaque stability and disease symptomatology) may not be powered enough. Second, the time interval between symptoms and endarterectomy in our cohorts has been variable (2 weeks to 3 months), complicating the search for correlations with the histopathologic plaque phenotype. Third, the analysis of TLR7 associations with inflammatory and tissue remodeling markers of plaque vulnerability has been done at the mRNA level and is based on a single cohort of patients (BiKE), raising the possibility that, at the protein level and in other cohorts, such observations may differ. Thus, more studies using carefully defined and larger cohorts of patients will be needed to ultimately determine whether increased TLR7 expression also translates to fewer acute clinical events in humans.
In summary, our study extends current knowledge on the role of innate immunity in atherosclerosis. It adds into the frame TLR7, a receptor that plays a protective role by limiting inflammatory macrophage activation and atherosclerotic lesion development and vulnerability. This challenges the prevailing concept that all TLRs are pathogenic in atherosclerosis and exposes the need for more detailed investigation of the role of innate immunity receptors and pathways in this disease. Unraveling the complex molecular machinery involved in TLR7-mediated atheroprotection should therefore be of great value for understanding homeostasis of the vessel wall and for identifying regulatory steps of therapeutic potential. 
CLINICAL PERSPECTIVE
Atherosclerosis underlying cardiovascular mortality is the leading cause of death in developed countries. Efforts are therefore concentrating on unwinding the pathophysiological mechanisms controlling its development and clinical complications. Among them, Toll-like receptors (TLRs) have taken center stage in atherosclerosis research by virtue of their ability to sense danger in response to hypercholesterolemia, tissue stress, or necrosis, and drive macrophage activation and inflammation in the vessel wall. TLR2 and TLR4, in particular, have been shown to play a critical role in promoting plaque development and vulnerability leading to the view that all TLRs are pathogenic for this disease. This article now reports the surprising finding that TLR7, an endosomal TLR that recognizes viral single-stranded RNA and self-RNA released from necrotic cells, is protective. In experimental atherosclerosis in mice, TLR7 prevented lesion development, stenosis, and plaque vulnerability by constraining monocyte chemoattractant protein-1 production, Ly6C hi "inflammatory" monocyte expansion and M1 inflammatory macrophage accumulation to developing atherosclerotic lesions. In human carotid endarterectomy specimens, TLR7 was positively associated with an M2 anti-inflammatory macrophage signature and collagen genes and inversely related/unrelated to proinflammatory mediators and platelet markers, whereas TLR7 activation in human atheroma cultures selectively suppressed the production of monocyte chemoattractant protein-1. Altogether, these findings reveal that TLR7 is part of a protective response that limits atherosclerotic plaque development and vulnerability and challenge the prevailing concept that all TLRs are pathogenic. They also provide new insight about the complex interplay of innate immunity in atherosclerosis and support the exploitation of the TLR7 pathway for therapy.
